Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc is trading at $39.06, down 0.43% on the session. The 50 day average sits at $42.82 and the 200 day at $35.07, which puts the stock in a uptrend. RSI is at 40.3, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $38.51 with resistance near $42.12, so that band frames the current range. Average daily movement is roughly $2.06, or about 5.3% of the share price, which is what any stop placement has to allow for. The overall health score of 44 out of 100 combines a trend score of 53, momentum of 24 and a risk score of 58.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.